n18
CELEBS|Corporate
   |
Everything
Rakesh Jain

Business Leaders

Rakesh Jain

In.com User Rating
0 Ratings
Rate this celeb now!"
15 Like 27 Dislike

About Rakesh Jain

Rakesh K. Jain is the Andrew Werk Cook Professor of Tumor Biology at Massachusetts General Hospital in the Harvard Medical School. Dr. Jain primarily researches tumor pathophysiology. His work on cancer therapies led to discovery of an alternate use of Herceptin, an anti-tumor cell pharmaceutical compound produced by Genentech, as an inhibitor for blood vessel growth necessary for tumor growth.[1] His award-winning work on tumor biology has been recognized by a number of professional recognitions, including the following awards in 2006: Distinguished Service Award, Nature Biotechnology-Miami Symposium on Angiogenesis Outstanding Achievement Award, Society of American Asian Scientists in Cancer Research Robert L. Krigel Lecture, Fox Chase Cancer Center, Philadelphia Alpha Chi Sigma Research Award, American Institute of Chemical Engineers Benjamin Zweifach Distinguished Lecture, The

Read More

tAKE YOUR pICK

Which is a better Public Sector Bank stock to invest in?

SBI
Pick

SBI

V/S
Bank Of India
Pick

Bank Of India

Disclaimer: Network18 Media & Investments Limited is proposing, subject to market conditions and other considerations, an offer of its equity shares on rights basis and has filed a Draft Letter of Offer with the Securities and Exchange Board of India. The Draft Letter of Offer is available on the website of SEBI at www.sebi.gov.in and the websites of the Lead Managers at www.icicisecurities.com and www.rbs.in. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to "Risk Factors" in the Draft Letter of Offer. The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or any state securities laws in the United States and may not be offered or sold in the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S under the US Securities Act) except in a transaction exempt from the registration requirements of the US Securities Act and in accordance with any applicable U.S. state securities laws.